On July 1, 2024, the Food and Drug Administration (FDA) issued three citations to Newpharma, Inc. in Miami following an inspection that examined food composition, standards, labeling, and economic factors, according to data posted on the FDA’s website.
The FDA website indicates that the citations were delivered to the company as follows:
- ‘Your quality control personnel did not determine that specifications established for the production and process control system were met.’
- ‘Your quality control personnel did not reject a dietary supplement when an established specification was not met.’
- ‘You did not establish written procedures for the requirements for packaging received.’
The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.
According to its website, the FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety and quality.
Information in this article was obtained from the U.S. Food and Drug Administration. The source data can be found here.
